ERK1/2 Promotes cigarette smoke-induced rat pulmonary artery smooth muscle cells proliferation and pulmonary vascular remodeling via up-regulating cycline1 expression

This study investigated the potential role of ERK1/2-cyclinE1 signaling pathway in rat pulmonary artery smooth muscle cells (rPASMCs) proliferation and pulmonary vascular remodeling induced by cigarette smoke exposure. A total of 24 male Wistar rats were randomly divided into 4 groups: control group (C group), S-1M, S-3M and S-6M groups (animals in the groups were exposed to smoke for 1, 3, and 6 months, respectively). HE staining and anti-α-smooth muscle actin antibody staining were performed to observe the degree of pulmonary vascular remodeling. Immunohistochemis- try and Western blotting were performed to evaluate ERK1/2 and cyclinE1 expression in pulmonary vessels. Primary cultured rat pulmonary artery smooth muscle cells (rPASMCs) were exposed to ciga- rette smoke extract (CSE). ERK inhibitor (PD98059) and cyclinE1 siRNA were used to verify the role of ERK1/2 and cyclinE1 in CSE-induced rPASMCs proliferation. Cell proliferation was assessed by cell counting and 5-bromo-2-deoxyuridine (BrdU) incorporation. Our results showed that abnormal pulmo- nary vascular remodeling was found in cigarette smoked rats. Compared to C group, activated ERK1/2 and cyclinE1 expression was significantly increased in smoke-exposure groups. This up-regulated ex- pression was positively correlated with the severity of pulmonary vascular remodeling, and there was positive correlation between the expression of ERK1/2 and cyclinE1. PD98059 and cyclinE1 siRNA in- hibited the proliferation of rPASMCs. The expression of cyclinE1 could be down-regulated by PD98059. Our data demonstrated that increased expression of ERK1/2 and cyclinE1 might be involved in the pathogenesis of abnormal rPASMCs proliferation and rat pulmonary vascular remodelling induced by cigarette smoke exposure.     

社区获得性肺炎患者发生临床严重事件的预测方法研究

目的 探讨社区获得性肺炎(CAP)患者发生临床严重事件的独立影响因素,寻找简便、有效、更准确的预测方法.方法 回顾性分析我院呼吸与危重症医学科2018年8月至2019年7月间诊断为CAP患者的临床资料,以住院期间发生临床严重事件(入住重症加强治疗病房、使用机械通气或血管活性药物、30天内死亡)为终点事件,将患者分为严重...     

非HIV感染低淋巴细胞血症肺隐球菌病患者的临床特征分析

目的 分析非HIV感染低淋巴细胞血症肺隐球菌病(PC)患者的临床特征。方法根据外周血淋巴细胞计数正常范围低限值将104例PC患者分为低淋巴细胞组(32例)与对照组(72例),比较两组患者的一般临床资料、白蛋白水平、临床特征、影像学特征、治疗方式及预后情况。结果 临床特征方面,低淋巴细胞组年龄、头痛、肺外播散、中枢神经系统(CNS)受累比例均高于对照组,无症状比例低于对照组;影像学特征方面,低淋巴细胞组病灶类型为结节肿块型比例低于对照组,伴随征象为空洞及胸腔积液比例均高于对照组;治疗方式及预后方面,低淋巴细胞组手术+抗真菌及单抗真菌治疗、完全缓解及治疗有效比例均低于对照组,稳定及死亡比例均高于对照组(P<0.05)。结论 低淋巴细胞的PC患者年龄大、临床症状多,容易发生肺外播散,影像学表现为结节肿块型的比例较低,出现空洞及胸腔积液的比例较高,预后较差。